- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
Biophan Technologies, Inc. (OTC BB: BIPH.OB), a developer of next-generation biomedical technology, today announced the results of their operations for the first quarter ended May 30, 2008.
During the quarter ended May 30, 2008, the Company continued it's commitment to invest in the Myotech Circulatory Support System (CSS) and entered into the next stage of development, with a sharpened focus on the acute resuscitation market segment, where there is a large patient population not adequately served by existing technologies. In addition, Myotech secured a Memorandum of Understanding with PPA Technologies in Germany, a potential strategic partner for the development of the Myotech Circulatory Support System, which Biophan expects to be approved for sale in the US, in 24-30 months.
Biophan also expanded its intellectual property through the acquisition of the patent portfolio from Nanoset, LLC, which provides broad coverage on novel medical uses of nanomagnetic materials. And, the Company saw the issuance of two new patents expanding coverage of the biothermal power supply and providing coverage for an optical MRI catheter system, which is a continuation of its core strategy of pursuing grants and strategic partnerships for the development of its earlier stage technologies.
The Company ended the quarter with $5.7 million in cash, and recognized revenue from license fees and testing and consulting services of $0.22 million.
About Biophan Technologies, Inc.
Biophan is dedicated to providing technologies that offer innovative and competitive advantages to the medical device industry. The Company is helping to commercialize the Myotech Circulatory Support System, which has significant potential to improve the treatment of acute heart failure. Biophan Technologies, Inc. holds a 70% interest in Myotech with rights to acquire additional equity, and is leading Myotech's business development efforts. Biophan is traded on the OTC market under the symbol BIPH, and is also listed on the Frankfurt Stock Exchange under the symbol BTN.
Cautionary Statement Regarding Forward-Looking Statements
Certain statements included in this press release may constitute forward-looking statements within the meaning of applicable securities laws. These statements reflect what Biophan anticipates, expect, or believe may happen in the future. Biophan's actual results could differ materially from the outcome or circumstance expressed or implied by such forward-looking statements as a result of a variety of factors including, but not limited to: Biophan's ability to develop its technologies; the approval of Biophan's patent applications; the successful implementation of Biophan's research and development programs; the ability of Biophan to demonstrate the effectiveness of its technology; the acceptance by the market of Biophan's technology and products incorporating such technology; the ability of Biophan to effectively negotiate and enter into contracts with medical device manufacturers for the licensing of Biophan's technology; competition; the ability of Biophan to raise capital to fund its operating and research and development activities until it generates revenues sufficient to do so; and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in Biophan's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with Biophan's periodic filings with the SEC, which are incorporated herein by reference. The forward-looking statements contained herein are made only as of the date of this press release, and Biophan undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.
For more information, please click here
Biophan Technologies, Inc.
Copyright © Biophan Technologies, Inc.If you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
Doubling down on Schrödinger's cat May 27th, 2016
Deep Space Industries and SFL selected to provide satellites for HawkEye 360’s Pathfinder mission: The privately-funded space-based global wireless signal monitoring system will be developed by Deep Space Industries and UTIAS Space Flight Laboratory May 26th, 2016
Doubling down on Schrödinger's cat May 27th, 2016
Programmable materials find strength in molecular repetition May 23rd, 2016
Syracuse University chemists add color to chemical reactions: Chemists in the College of Arts and Sciences have come up with an innovative new way to visualize and monitor chemical reactions in real time May 19th, 2016
Arrowhead to Webcast Fiscal 2015 Year End Results December 7th, 2015
Haydale Announce Year End Results November 3rd, 2015
Keysight Technologies Begins Trading as Independent Company November 3rd, 2014